At the time of writing, Janux Therapeutics Inc [JANX] stock is trading at $40.03, up 3.62%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The JANX shares have gain 11.60% over the last week, with a monthly amount glided 0.55%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Janux Therapeutics Inc [NASDAQ: JANX] stock has seen the most recent analyst activity on March 21, 2024, when BTIG Research initiated its Buy rating and assigned the stock a price target of $62. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on March 20, 2024, and set its price target to $100. On April 06, 2023, Wedbush initiated with a Outperform rating and assigned a price target of $24 on the stock. William Blair started tracking the stock assigning a Outperform rating.
For the past year, the stock price of Janux Therapeutics Inc fluctuated between $5.65 and $58.69. Currently, Wall Street analysts expect the stock to reach $62 within the next 12 months. Janux Therapeutics Inc [NASDAQ: JANX] shares were valued at $40.03 at the most recent close of the market. An investor can expect a potential return of 54.88% based on the average JANX price forecast.
Analyzing the JANX fundamentals
According to Janux Therapeutics Inc [NASDAQ:JANX], the company’s sales were 8.08M for trailing twelve months, which represents an -13.50% plunge. Gross Profit Margin for this corporation currently stands at 0.76% with Operating Profit Margin at -9.03%, Pretax Profit Margin comes in at -7.21%, and Net Profit Margin reading is -7.21%. To continue investigating profitability, this company’s Return on Assets is posted at -0.15, Equity is -0.18 and Total Capital is -0.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 38.79 points at the first support level, and at 37.56 for the second support level. However, for the 1st resistance point, the stock is sitting at 40.90, and for the 2nd resistance point, it is at 41.78.
Ratios To Look Out For
It is important to note that Janux Therapeutics Inc [NASDAQ:JANX] has a current ratio of 26.80. Further, the Quick Ratio stands at 26.80, while the Cash Ratio is 1.47. Considering the valuation of this stock, the price to sales ratio is 255.93, the price to book ratio is 5.38.
Transactions by insiders
Recent insider trading involved Avalon Ventures XI, L.P., 10% Owner, that happened on Nov 13 ’23 when 0.85 million shares were purchased. Acting Chief Financial Officer, Reardon Tighe completed a deal on Nov 13 ’23 to buy 0.85 million shares. Meanwhile, Director Lichter Jay bought 0.85 million shares on Nov 13 ’23.
